Moderna set to join the Nasdaq-100 index, replacing Warner Bros. Discovery on October 9, 2026
Executive summary: Nasdaq announced that Moderna, Inc. (MRNA) will join the Nasdaq-100 Index®, replacing Warner Bros. Discovery, Inc. (WBD) prior to market open on October 9, 2026. Index inclusion typically triggers buying from passive funds that track the Nasdaq-100, potentially increasing demand for Moderna shares and reducing weight for the outgoing company.
Who is involved: Moderna, Nasdaq (NDAQ), and Warner Bros. Discovery (WBD).
Likely next: The index rebalancing will occur on October 9, 2026; thereafter, ETFs such as the Invesco QQQ Trust will adjust their holdings to reflect the new composition.
Nasdaq's announcement that Moderna will become a component of the Nasdaq-100 index reflects the company's growth and market capitalization, displacing Warner Bros. Discovery. The change will take effect before market open on Friday, October 9, 2026, and will adjust the index composition for the first time since the regular quarterly review. This move increases Moderna's visibility to index‑linked funds and could lead to passive inflows, while the outgoing stock will see a corresponding reduction in weight.
What's next — scenarios
Passive Inflow Surge (60%)
Moderna shares experience upward price pressure and increased liquidity prior to October 9, 2026, driven by mandatory buying from index-tracking funds.
- Announcement of estimated passive fund rebalancing volume exceeding 15 million shares
- Outperformance of Moderna relative to the broader biotech sector in late September 2026
Neutral Rebalancing (30%)
The market absorbs the transition smoothly with negligible net volatility as arbitrageurs fully price in the index inclusion well in advance.
- Moderna trading volume spikes moderately without significant directional price movement in the final week of September 2026
- Derivative markets show balanced put/call open interest leading up to the effective date
Post-Inclusion Sell-Off (10%)
Moderna gives up pre-announcement gains as short-term traders 'sell the news' immediately following the October 9 effective date.
- Sharp spike in short interest reported for Moderna during the first week of October 2026
- Broader market downturn overshadows the index inclusion catalyst
What to watch
- Nasdaq official daily volume reports for Moderna during the final week of September 2026
- Statement of asset allocation adjustments from major Nasdaq-100 ETF providers by October 5, 2026
- Price action and liquidity metrics of Warner Bros. Discovery as it exits the index on October 9, 2026
Timeline
- — Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026 (GlobeNewswire)
Analysis — what this means
Likely next events
- Nasdaq-100 index rebalancing on October 9, 2026
Sectors affected
- Biotechnology
- Pharmaceuticals
- Index funds and ETFs tracking the Nasdaq-100
Key entities
Sources
Related cases
- Iyuno unveils CLOE platform with persistent contextual memory to streamline modern localization workflows
- Major tech and biotech stocks enter buy zones as broader indices hold steady
- Suze Orman says a breakup saved an investor more than Moderna's 180% stock surge
- Moderna's market valuation jumps $30 billion on confidence in its cancer vaccine successes
- Moderna’s mRNA melanoma vaccine success drives 176% stock jump, validating cancer immunotherapy platform
- Moderna secures US approval for its first mRNA flu vaccine for adults 50+, overcoming initial Trump administration hesitations